Virobix | Targeted Gene Delivery to Treat Cancer

The Challenge

Cytokines and immunotherapies are potent cancer killers. The clinical bottleneck is not efficacy: it is precision delivery to solid tumors.

Current approaches compromise on safety, viral fitness, or tumor penetration. Native cytokines are too toxic systemically. Modified viral coats reduce fitness and scalability. Non-viral delivery lacks amplification and penetration.

Virobix is developing a targeted RNA delivery platform that decouples potency from targeting, enabling safe systemic delivery of therapeutic payloads directly to tumor cells.

80-90% Late-stage tumors express our lead target marker (CEACAM6)

$165B+ Global solid tumor drug market

$1-2B Market per CEACAM6 indication (EU+US)

Our Technology

De-coupling potency from targeting via a non-modified viral backbone + modular tumor-binding engager

Virobix VSV-based oncolytic virus platform

VSV Viral Backbone

Non-pathogenic in humans
Coat unmodified, full viral fitness
Self-amplifying payload delivery
Clinical safety data (200 patients)

Modular Engager

Bridges viral coat to tumor surface
Rapid marker switching
Fully human, non-immunogenic
Lead: CEACAM6 • Expansion: PSMA

Flexible RNA Payload

Cytokines, immune stimulators, or checkpoint inhibitors
Promoter-controlled local expression
Activates immunologically “cold” tumors
Broad immune activation potential

Key Advantages

Systemic IV Delivery

Intravenous administration for full-body reach

Selective & Safe

No normal tissue sequestration or off-target effects

Immune-Shielded Vector

Coated VSV requires receptor-mediated entry

Programmable

Modular design enables rapid marker switching

Development Pipeline

From validated proof-of-concept to clinical development

Lead Asset

CEACAM6: Late-Stage Solid Tumors

Pancreatic, colorectal, ovarian, and lung cancers. CEACAM6 is a marker for poor prognosis, expressed in 80-90% of late-stage tumors in these indications.

Status: In-vitro POC confirmed, initial in-vivo validation complete

Expansion

PSMA: Prostate Cancer

Expansion-ready via modular engager swap. PSMA targeting validated in vitro.

Status: Early validation

Development Roadmap

Completed

Engager discovery & optimization. In-vitro POC. In-vivo tumor entry. 2 patents filed. External validation.

Bridge (6-9 months)

Virus insert selection & optimization. Engager candidate selection. Biological validation. Early immune activation.

Pre-Seed (18-24 months)

Mechanism & in-vivo PK/PD. Preliminary safety. Organoid efficacy studies. CMC development. Pre-IND planning.

Seed (24-36 months)

Non-human primate safety. IND filing. First-in-human study (Israel). Phase 1 preparation.

Our Team

Cytokine and viral experts with proven lab-to-therapeutic execution

Dr. Diana Gataulin

CEO & Co-Founder

PhD Biochemistry, Weizmann Institute. Technology co-inventor. IP commercialization strategist with prior patent licensing success. BD and fundraising lead.

Dr. Eyal Zoler

CSO & Co-Founder

PhD Biochemistry, Weizmann Institute. Extensive experience in cytokines, viruses, and protein purification. Core experimental execution and lab-to-therapeutic translation.

Prof. Menachem Rubinstein

Scientific Advisor

40+ years leading biochemical research at Weizmann Institute. Core technology inventor. Inventor of 70+ patents including Roferon-A® (Roche), Rebif® (Merck), and Enbrel® (Amgen).